Veeda Clinical Research IPO Details
MAINBOARD
Veeda Clinical Research IPO DRHP (Draft Red Herring Prospectus) has been SEBI Approval Received.
The Lead Managers for Veeda Clinical Research IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Axis Capital Ltd, Clsa India Pvt Ltd, IIFL Capital Services Ltd, SBI Capital Markets Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Veeda Clinical Research Limited DRHP.
Veeda Clinical Research IPO Details
Veeda Clinical Research IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
To be announced | |||
Veeda Clinical Research IPO Reservation
Promoter Holding
Documents
Veeda Clinical Research IPO Valuations
Veeda Clinical Research Financial Information
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 1,891.86 | 2,040.21 | 734.77 | 677.54 |
| Revenue | 315.87 | 407.99 | 420.21 | 293.11 |
| Profit After Tax | -24.93 | -0.36 | 42.42 | 50.46 |
| Net Worth | 1,192.51 | 1,190.96 | 564.9 | 503.21 |
| Reserves and Surplus | 1,048.91 | 1,047.37 | 446.58 | 419.58 |
| Total Borrowing | 405.49 | 261.69 | 48.57 | 47.2 |
| Amount in ₹ Crore | ||||
About Veeda Clinical Research IPO
Founded in April 2004, Veeda Clinical Research Limited is a full-service contract research organization (CRO) providing a comprehensive range of services in drug development, including non-clinical, pre-clinical, bioavailability, bioequivalence studies, and clinical trials for various drugs such as novel entities, generics, and biosimilars, as well as medical devices.
The company's services include the following.
-
Early-phase and late phase clinical trials
- Healthy volunteer studies (“HVS”) which include bioavailability studies and bioequivalence studies
-
Pre-clinical trials and non-clinical testing
- biopharma services include non-clinical analysis and clinical bioanalysis of large molecules.
As of September 30, 2024, the company completed 119 global regulatory inspections in HVS and Pre-Clinical services by authorities including the FDA, UK-MHRA, WHO, ANVISA, DCGI, EMA, and NPRA.
As of September 30, 2024, the company has over 436 active clients worldwide.
The company has successfully conducted studies for 417, 504, 498, and 580 clients during the six months ending September 30, 2024, and for the financial years 2024, 2023, and 2022, respectively.
As of September 2024, the company employs 914 people in various departments.
Competitive Strengths:
- Established quality credentials with a strong focus on quality control management.
- Successful integration of growth opportunities through acquisitions.
- Global and diverse management team with deep scientific expertise.
Strength Of Veeda Clinical Research IPO
Risk Of Veeda Clinical Research IPO
Objectives Veeda Clinical Research IPO
- Capital expenditure towards procurement of equipment and machinery for the Company;
- Investment in the Material Subsidiary, Bioneeds India Private Limited for capital expenditure towards procurement of equipment and machinery;
- Investment in the Material Subsidiary, Bioneeds India Private Limited, for repayment/pre-payment, in part or full of certain borrowings of theSubsidiary, Bioneeds India Private Limited; Funding organic growth of the Company, the Material Subsidiary, Bioneeds India Private Limited and Health Data Specialists (Holdings) Limited through marketing and promotional activities, updation of technology and adoption of modern digital solutions in our workflows to enhance the efficiency and quality assurance of the operating processes and data management; and
- General corporate purposes.
Company Contact Details
Veeda Clinical Research Ltd.
Shivalik Plaza –A, 2nd Floor
Opposite Ahmedabad Management Association
Ambawadi
Ahmedabad, Gujarat, 380015
Phone: +91 79 6777 3000
Email: investor.relation@veedalifesciences.com
Website: https://veedalifesciences.com/
Registrar Contact Details
Veeda Clinical Research IPO - FAQs
The Veeda Clinical Research IPO is a MAINBOARD public issue comprising 0 equity shares with a face value of ₹2 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
MUFG Intime India Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at TBA.